Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Zelnorm Tip The Scales To Increased Drug Safety Oversight Thru PDUFA?

Executive Summary

Novartis' suspension of marketing of Zelnorm could add momentum to efforts to attach drug safety reform language to the Prescription Drug User Fee Act reauthorization legislation

You may also be interested in...



Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says

Novartis is emphasizing that the removal of Zelnorm from the market is a suspension rather than a withdrawal

Rx Safety Bill Would Require Renegotiation Of User Fees, FDA Tells Senate

An expansion of FDA's drug safety authorities as envisioned by legislation from Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., would require a renegotiation of user fees with industry, Commissioner Andrew von Eschenbach said

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter

Latest News
See All
UsernamePublicRestriction

Register

PS048239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel